Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03427125 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
A Phase 3 study, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,559
- Enrollment target
NCT03427125 is a Phase 3 study that has completed, run by Ardelyx. The registered enrollment target is 1,559 participants.
The verdict
NCT03427125, a Phase 3 study, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,559 participants
- Enrollment target
Study Summary
This Phase 3, 26-week, open label study with a 12-week, placebo-controlled, randomized withdrawal period followed by an open label long term safety extension will evaluate the safety and efficacy of tenapanor to treat hyperphosphatemia in end-stage renal disease (ESRD) on hemodialysis and peritoneal dialysis.
Interventions
- DRUG Placebo
- DRUG Tenapanor
- DRUG Sevelamer Carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,559 participants |
| Start Date | 2018-01-08 |
| Est. Completion | 2020-02-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03427125
The ClinicalTrials.gov registry entry for NCT03427125 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,559 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03427125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03427125 about?
NCT03427125 is a clinical study titled "A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis". This Phase 3, 26-week, open label study with a 12-week, placebo-controlled, randomized withdrawal period followed by an open label long term safety extension will evaluate the safety and efficacy of tenapanor to treat hyperphosphatemia in end-stage renal disease (ESRD) on hemodialysis and peritoneal...
What is the current status of trial NCT03427125?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,559 participants. The study started on 2018-01-08. Estimated completion is 2020-02-27.
What interventions are being tested in trial NCT03427125?
The interventions under investigation include: Placebo (DRUG), Tenapanor (DRUG), Sevelamer Carbonate (DRUG).
Who is sponsoring clinical trial NCT03427125?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.